Information Provided By: 
Fly News Breaks for August 2, 2019
TNDM
Aug 2, 2019 | 07:38 EDT
Oppenheimer analyst Steven Lichtman raised his price target for Tandem Diabetes to $84 from $80 following the company's Q2 results, saying sales exceeded expectations significantly, with sales and adjusted EBITDA guidance both raised. In a research note to investors, Lichtman says looking forward, the key drivers in his focus are the launch of Control-IQ in Q4 a now building renewal cycle, international expansion and what he continues to believe is an under-appreciated t:sport opportunity.
News For TNDM From the Last 2 Days
TNDM
Apr 25, 2024 | 06:13 EDT
TNDM
Apr 25, 2024 | 06:02 EDT
Leerink upgraded Tandem Diabetes to Outperform from Market Perform with a $45 price target.
